Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics Ltd. has announced a proposed issue of 25 million securities, which are options expiring on various dates and at various prices, set to be issued on April 15, 2025. This strategic move is likely to bolster the company’s financial position, potentially enhancing its capacity to further develop its CAR-T therapies and strengthen its market presence in the biotechnology sector.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on developing innovative cell therapies for cancer treatment. The company is engaged in advancing its pipeline of chimeric antigen receptor T cell (CAR-T) therapies, aiming to address unmet medical needs in oncology.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$7.98M
Learn more about CHM stock on TipRanks’ Stock Analysis page.